Saft primary lithium batteries help sleep apnea patients enjoy a better night’s rest

Saft LSH batteries provide three years of autonomous power for SRETT’s T4P universal telehealth solution for the remote monitoring of patients suffering from sleep apnea and treated by continuous positive airway pressure (CPAP) devices.

Paris, June 3rd, 2014 – Saft, the world’s leading designer and manufacturer of advanced technology batteries for industry, has been awarded a major contract from SRETT, a French company that specializes in M2M (machine to machine) monitoring systems.  In the framework of this contract, Saft is providing the primary lithium batteries that ensure ultra-reliable, fully autonomous operation for SRETT’s T4P telehealth solution for the remote monitoring of sleep apnea patients.

SRETT has designed the T4P, a remote monitoring solution for universal fitting to continuous positive airway pressure (CPAP) devices, used in the treatment of sleep apnea. Saft has been selected as the exclusive battery supplier for the overall programme.  Over the next three years, tens of thousands of its high power LSH series, D-size batteries will be fitted to T4P units.

Sleep apnea is a chronic respiratory disease that affects, in the Western world, between:

- 3 to 7% of all middle aged men and

- 2 to 3% of all middle aged women.

It is characterized by cessation of breathing during sleep. This condition induces drowsiness during the day and can lead to cardiovascular complications.

One of the most common and effective treatments for moderate to severe sleep apnea is the use of a continuous positive airway pressure (CPAP) device. This device keeps the patient's airway open during sleep by means of a flow of pressurized air into the throat. SRETT has designed the T4P as a universal remote monitoring solution for all types of CPAP devices on the market.

The T4P uses GPRS communication to automatically upload patient data to healthcare professionals, facilitating personalized and ongoing monitoring of their condition with the capability for immediate intervention should a problem occur.

‘Saft batteries are perfect for medical applications such as the new T4P device where failure is simply not an option’ said Pascal Hans, Sales Manager - France in Saft’s Specialty Battery Group. ‘This major contract with SRETT is further recognition that our LSH batteries offer the ultimate combination of reliability, performance and long life to meet the most stringent medical standards.”

Saft’s support team worked closely with SRETT to evaluate the optimum battery solution for T4P. This was identified as the LSH20 lithium thionyl chloride (Li-SOCl2) 3.6 V primary battery. This battery features a robust spiral construction offering high voltage response and high drain/pulse capability as well as a low self-discharge rate. The LSH20 is designed for ease of integration into compact systems such as the T4P, where it will ensure a minimum operational life of three years.